asiRNA Complexes Targeting ANGPT2 and PDGFB for Angiogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for angiogenesis-associated diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME) often lead to secondary complications like geographic atrophy, and existing therapies do not effectively inhibit abnormal blood vessel growth without significant side effects.
Innovation Solution
Development of RNA complexes, specifically asymmetric shorter-duplex small interfering RNAs (asiRNAs) targeting ANGPT2 and PDGFB, which can inhibit angiogenesis by penetrating cellular membranes without delivery vehicles, formulated into pharmaceutical compositions for various delivery methods including intravitreal and oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If VEGF inhibitors are used to treat wet AMD, then abnormal blood vessel growth is inhibited, but geographic atrophy develops as a secondary complication
Solution Approach 1:
The patent segments the anti-angiogenic therapy by using different RNA complexes targeting different angiogenesis-related genes (ANGPT2 and PDGFB) instead of relying on a single VEGF inhibitor pathway. This multi-target approach addresses abnormal blood vessel growth through multiple mechanisms while potentially reducing off-target effects that cause geographic atrophy
Solution Approach 2:
The patent employs chemical modifications to the RNA complexes (such as 2′-O-methylated nucleosides, phosphorothioate bonds, and hydrophobic moieties like cholesterol) to change the physical and chemical parameters of the therapeutic agent. These modifications enhance cellular membrane penetration, stability, and specificity while reducing cytotoxicity and off-target effects
2Reliability
If RNA complexes are designed to penetrate cellular membranes without delivery vehicles, then therapeutic efficacy is improved, but complexity of delivery system is reduced
Solution Approach 1:
The RNA complexes are designed with self-delivery capabilities through incorporation of hydrophobic moieties (such as cholesterol) and chemical modifications that enable them to penetrate cellular membranes autonomously without requiring external delivery vehicles like liposomes or transfection reagents. This self-service approach simplifies the overall delivery system while maintaining high therapeutic efficacy
Solution Approach 2:
The patent creates composite RNA structures by combining nucleic acid sequences with chemical modifications and hydrophobic moieties. These composite materials integrate the therapeutic RNA function with membrane-penetrating properties, eliminating the need for separate delivery vehicle components
3Reliability
If existing therapies inhibit abnormal blood vessel growth, then angiogenesis is reduced, but significant side effects occur
Solution Approach 1:
The patent uses RNA complexes as intermediary agents that specifically bind to and silence target mRNAs (ANGPT2 and PDGFB) through complementary base pairing. This intermediary mechanism provides highly specific gene silencing that selectively inhibits angiogenesis-related pathways while minimizing off-target effects and systemic side effects associated with conventional small molecule inhibitors
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNA complexes effectively inhibit ANGPT2 and PDGFB expression, reducing angiogenesis and potentially treating AMD, DME, and cancer by directly targeting the underlying cause of abnormal blood vessel growth without cytotoxicity.
Implementation Method 1
an antisense strand having sequence complementarity to an ANGPT2 or PDGFB mRNA sequence and a sense strand having sequence complementarity to the antisense strand
Implementation Method 2
the modification is a 2′-O-methylated nucleoside, a phosphorothioate bond or a hydrophobic moiety. In some embodiments, the chemical modification is a hydrophobic moiety. In some embodiments, the hydrophobic moiety is a cholesterol moiety
Data Source
AI summary
In certain aspects, provided herein are RNA complexes (e.g., asymmetric RNA complexes, such as asiRNAs or cell penetrating asiRNAs) that inhibit ANGPT2 and/or PDGFB expression and are therefore useful for treating angiogenesis-associated diseases, such as cancer, AMD, and DME.